BioMarin entered into a binding term sheet with Ascendis Pharma to resolve all pending global patent litigation regarding the TransCon CNP asset, navepegritide (Yuviwel). Under the agreement, BioMarin grants Ascendis a non-exclusive, worldwide license for Yuviwel across all indications. In exchange, Ascendis will pay royalties of 20% on U.S. net sales and 18% on net sales in the EU, Brazil, and South Korea until May 2030. The settlement includes retroactive royalty application from first commercial sale and dismissal of all related legal proceedings. BioMarin is a biotechnology company focused on developing treatments for rare genetic diseases.
